Immunovia’s Next Generation Test for Early stage (I&II) detection of PDAC showed better results (with 98% specificity and 75% sensitivity) vs IMMray Pancan-d test that uses CA19-9 as a biomarker
The Model Development study was designed to trace the highest-performing biomarker for its inclusion in the Next generation test. The study compared 481 samples of cases (133 Patients with stage I&II PDAC) with 384 samples of controls (Healthy individuals and people at high risk of cancer, and other underlying diseases)
The results for the P-II of the study that involves statistical analysis to improve and evaluate the reliability of tests for patients are expected in 6-8 wks
Ref: Immunovia | Image: Immunovia
Related News:- The US FDA Grants Orphan Drug Designation to Candel Therapeutics’ CAN-2409 as a Treatment for Pancreatic Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
